Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.

Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis and stimulate liver regeneration. In a multicenter, open-label, parallel-group, phase 2 randomized controlled trial ( ISRCTN10368050 ) in n = 51 adult patients with compensated cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥10 and ≤17, we evaluated the efficacy of autologous monocyte-derived macrophage therapy (n = 27) compared to standard medical care (n = 24).

Whole System Approach to designing, implementing and measuring health and performance benefits of improving diet behaviour in a military setting.

Many employers-including the military-are experiencing systemic workforce capacity and capability challenges. This coincides with a time of declining workforce health, especially among military service entrants, where many performance-limiting health conditions are preventable if healthier behaviours are practised. Effectively tackling complex, interconnected health problems demands a multilevel, multicomponent Whole System Approach (WSA).

Valuing Health and Performance: A Case for Prioritizing Nutrition.

Introduction: Improving the dietary behaviors of personnel can result in positive impact beyond the individual, creating benefits for their organization and wider society. Military personnel endure extended periods of physical and cognitive activity. Healthful dietary behaviors by military personnel support preparedness; yet poor diet behaviors remain common and persistent, and adversely impact health and physical and cognitive performance.

The Scottish Hepatology Access Research Partnership (SHARP) improving access to liver services throughout Scotland.

Background And Aims: Scotland has the highest rate of deaths from chronic liver disease (CLD) in the UK. Socioeconomic and geographic isolation represent significant challenges to delivery of care. The multidisciplinary Scottish Hepatology Access Research Partnership (SHARP) aimed to identify and break down barriers to diagnosing and treating liver disease in Scotland.

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver.

Hepatic steatosis is a central phenotype in multi-system metabolic dysfunction and is increasing in parallel with the obesity pandemic. We use a translational approach integrating clinical phenotyping and outcomes, circulating proteomics, and tissue transcriptomics to identify dynamic, functional biomarkers of hepatic steatosis. Using multi-modality imaging and broad proteomic profiling, we identify proteins implicated in the progression of hepatic steatosis that are largely encoded by genes enriched at the transcriptional level in the human liver.